Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KITE 718

Next Previous
X
Search
Drug Profile

KITE 718

Alternative Names: KITE-718; MAGE-A3/A6 T cell receptor engineered T cells - Kite Pharma; MAGE-A3/A6 TCR engineered T lymphocytes - Kite Pharma

Latest Information Update: 04 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kite Pharma
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 25 Aug 2023 Kite Pharma terminates a phase I trial in Solid tumours (Late stage disease, Metastatic disease, Recurrent, Second line therapy or greater) in USA (IV) due to sponsor's decision to discontinue the trial (NCT03139370)
  • 15 Nov 2021 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (Kite Pharma pipeline, November 2021)
  • 26 Aug 2020 Phase I development in Solid-tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) is ongoing in USA (IV) (Gilead Sciences pipeline, August 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top